"Lipoprotein Lipase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 3.1.1.34.
Descriptor ID |
D008071
|
MeSH Number(s) |
D08.811.277.352.100.430
|
Concept/Terms |
Lipoprotein Lipase- Lipoprotein Lipase
- Lipase, Lipoprotein
- Diglyceride Lipase
- Lipase, Diglyceride
- Heparin-Clearing Factor
- Factor, Heparin-Clearing
- Heparin Clearing Factor
- Post-Heparin Lipase
- Lipase, Post-Heparin
- Post Heparin Lipase
- Postheparin Lipase
- Lipase, Postheparin
- Postheparin Lipoprotein Lipase
- Lipase, Postheparin Lipoprotein
- Lipoprotein Lipase, Postheparin
- Diacylglycerol Lipase
- Lipase, Diacylglycerol
- Lipemia-Clearing Factor
- Factor, Lipemia-Clearing
- Lipemia Clearing Factor
|
Below are MeSH descriptors whose meaning is more general than "Lipoprotein Lipase".
Below are MeSH descriptors whose meaning is more specific than "Lipoprotein Lipase".
This graph shows the total number of publications written about "Lipoprotein Lipase" by people in this website by year, and whether "Lipoprotein Lipase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
1997 | 2 | 0 | 2 |
1998 | 3 | 1 | 4 |
1999 | 2 | 0 | 2 |
2000 | 2 | 2 | 4 |
2001 | 3 | 1 | 4 |
2002 | 1 | 1 | 2 |
2003 | 1 | 3 | 4 |
2006 | 2 | 0 | 2 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 1 | 2 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipoprotein Lipase" by people in Profiles.
-
An overview of persistent chylomicronemia: much more than meets the eye. Curr Opin Endocrinol Diabetes Obes. 2025 Apr 01; 32(2):75-88.
-
Genetic Variants in Severe Hypertriglyceridemia Among Taiwanese Participants - Insights From Genome-Wide Association and Whole-Exome Sequencing Analyses. Circ J. 2025 Feb 25; 89(3):331-339.
-
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023 03; 29(3):729-737.
-
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Ann Hematol. 2020 Oct; 99(10):2343-2349.
-
Trilactic glyceride regulates lipid metabolism and improves gut function in piglets. Front Biosci (Landmark Ed). 2020 03 01; 25(7):1324-1336.
-
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018 Jan; 14(1):57-70.
-
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
-
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53.
-
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
-
Hyperglycemia-induced secretion of endothelial heparanase stimulates a vascular endothelial growth factor autocrine network in cardiomyocytes that promotes recruitment of lipoprotein lipase. Arterioscler Thromb Vasc Biol. 2013 Dec; 33(12):2830-8.